The
in vitro and
in vivo effects of Actmin
® (immunoactivator) on the prevention of immunosuppression by anesthesia and surgery were studied in dogs. In
in vitro studies, peripheral blood lymphocytes (PBL) were obtained from 16 dogs. PBL in group II (halothane treated group) were exposed to halothane for 20 minutes, whereas those in group I (halothane untreated group) were not exposed. Actmin, concanavalin A (Con A), or interleukin-2 (IL-2) was directly added to the PBL of both groups to compare the immunoactivation effect. In
in vivo studies, the preventive effects on immunosuppression after surgery were evaluated through changes in lymphoproliferative responses by Con A, phytohemagglutinin-P (PHA), and lipopolysaccaride (LPS) using 10 clinical cases. They were divided into the following two groups after surgery under general anesthesia. Five dogs in group B were administered Actmin (0.2 ml/kg, b.i.d.) orally after surgery for nine days. Five dogs in group A were not administered Actmin. Proliferative responses of group II were lower than those of group I at 3 day culture under the addition of Actmin. These responses of Actmin-added group were higher to those of Con A or IL-2-added group at 3 and 7 day culture. The stimulation index of Actmin-added group at 7 day culture was higher than that of the same group at 3 day culture.
In vivo, significant suppression in lympho-proliferation was observed after surgery in Actmin-unadded group. On the contrary, dogs that received oral administration of Actmin gave nonsuppressive proliferation to mitogen after surgery. These results suggest that Actmin produces higher immunoactivation compared with Con A and IL-2 and prevents immunosuppression after anesthesia and surgery in dogs.
View full abstract